Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic CancerTalia Golan, Hedy L. Kindler, Pascal Hammel et al.|New England Journal of Medicine|2019Cited by 2.2k
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomasYuchen Jiao, Laura D. Wood, Timothy M. Pawlik et al.|Nature Genetics|2013Cited by 709
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Chiara Cremolini, Luca Boni et al.|The Lancet Oncology|2022Cited by 268
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerHedy L. Kindler, Talia Golan, Pascal Hammel et al.|Journal of Clinical Oncology|2022Cited by 224
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal CancerThierry André, Sara Lonardi, Elena Élez et al.|New England Journal of Medicine|2024Cited by 208